Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened
ChemMedChem2013Vol. 8(8), pp. 1261–1265
Citations Over TimeTop 10% of 2013 papers
Stefan Peukert, Feng He, Miao Dai, Rui Zhang, Yingchuan Sun, Karen Miller‐Moslin, Michael McEwan, Bharat Lagu, Kate Wang, Naeem Yusuff, Aaron Bourret, Arun Ramamurthy, Wieslawa Maniara, Adam Amaral, Anthony Vattay, Anlai Wang, Ribo Guo, Jing Yuan, John Green, Juliet Williams, Silvia Buonamici, Joseph F. Kelleher, Marion Dorsch
Abstract
First disclosure: Continued optimization provided a novel type of Smoothened (Smo) antagonist based on a pyridazine core. The compound, NVP-LEQ506, currently in phase I clinical trials, combines high intrinsic potency and good pharmacokinetic properties resulting in excellent efficacy in rodent tumor models of medulloblastoma. Activity against a Smo mutant conferring resistance observed in a previous clinical trial with a competitor compound suggests additional therapeutic potential.
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- Коммуникaтивно- прaгмaтический aнaлиз дипломaтических бумaг (нa основе вербaльных нот)(2018)
- → ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ(2023)